JP2013155188A5 - - Google Patents

Download PDF

Info

Publication number
JP2013155188A5
JP2013155188A5 JP2013085785A JP2013085785A JP2013155188A5 JP 2013155188 A5 JP2013155188 A5 JP 2013155188A5 JP 2013085785 A JP2013085785 A JP 2013085785A JP 2013085785 A JP2013085785 A JP 2013085785A JP 2013155188 A5 JP2013155188 A5 JP 2013155188A5
Authority
JP
Japan
Prior art keywords
dalbavancin
amount
dose
bacterial infection
single doses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013085785A
Other languages
English (en)
Other versions
JP2013155188A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013155188A publication Critical patent/JP2013155188A/ja
Publication of JP2013155188A5 publication Critical patent/JP2013155188A5/ja
Pending legal-status Critical Current

Links

Claims (1)

  1. 少なくとも２つの治療上有効な１回分用量のダルババンシンおよび医薬上許容される担体を含有する、細菌感染の治療を要するヒトにおいて細菌感染を治療するための医薬であって、各１回分用量が５ないし１０日間隔で患者に投与され、最初の１回分用量のダルババンシンの量が５００ｍｇないし２０００ｍｇであり、最初の１回分用量のダルババンシンの量がその後の１回分用量に含まれるダルババンシンの量の少なくとも２倍である、医薬。
JP2013085785A 2002-11-18 2013-04-16 細菌感染の治療のためのダルババンシンの投与方法 Pending JP2013155188A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US42765402P 2002-11-18 2002-11-18
US60/427,654 2002-11-18
US48569403P 2003-07-08 2003-07-08
US60/485,694 2003-07-08
US49504803P 2003-08-13 2003-08-13
US60/495,048 2003-08-13
US49648303P 2003-08-19 2003-08-19
US60/496,483 2003-08-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011083790A Division JP2011157381A (ja) 2002-11-18 2011-04-05 細菌感染の治療のためのダルババンシンの投与方法

Publications (2)

Publication Number Publication Date
JP2013155188A JP2013155188A (ja) 2013-08-15
JP2013155188A5 true JP2013155188A5 (ja) 2014-05-15

Family

ID=32330046

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2004570384A Expired - Lifetime JP5519090B2 (ja) 2002-11-18 2003-11-14 細菌感染の治療のためのダルババンシンの投与方法
JP2011083790A Pending JP2011157381A (ja) 2002-11-18 2011-04-05 細菌感染の治療のためのダルババンシンの投与方法
JP2013085785A Pending JP2013155188A (ja) 2002-11-18 2013-04-16 細菌感染の治療のためのダルババンシンの投与方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2004570384A Expired - Lifetime JP5519090B2 (ja) 2002-11-18 2003-11-14 細菌感染の治療のためのダルババンシンの投与方法
JP2011083790A Pending JP2011157381A (ja) 2002-11-18 2011-04-05 細菌感染の治療のためのダルババンシンの投与方法

Country Status (15)

Country Link
US (12) US20050004011A1 (ja)
EP (1) EP1565201B1 (ja)
JP (3) JP5519090B2 (ja)
KR (2) KR101173310B1 (ja)
AU (3) AU2003299561A1 (ja)
CA (1) CA2506236C (ja)
DK (1) DK1565201T3 (ja)
ES (1) ES2712656T3 (ja)
HK (2) HK1083684A1 (ja)
HU (1) HUE041133T2 (ja)
IL (3) IL168327A (ja)
MX (1) MXPA05005338A (ja)
NO (1) NO20052362L (ja)
PT (1) PT1565201T (ja)
WO (3) WO2004045636A1 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101173310B1 (ko) * 2002-11-18 2012-08-10 비큐론 파마세티컬스 인코포레이티드 박테리아 감염 치료를 위한 달바반신 투여 방법
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
US20090062182A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched dalbavancin
US8389583B2 (en) * 2008-05-23 2013-03-05 Zurex Pharma, Inc. Antimicrobial compositions and methods of use
US20110132607A1 (en) * 2009-12-07 2011-06-09 Schlumberger Technology Corporation Apparatus and Technique to Communicate With a Tubing-Conveyed Perforating Gun
WO2015095658A1 (en) 2013-12-19 2015-06-25 Ge Healthcare Bio-Sciences Ab Remotely actuated valve for a biological liquid treatment system
US9649352B2 (en) * 2014-07-17 2017-05-16 The Medicines Company High purity oritavancin and method of producing same
RS61418B1 (sr) 2014-11-06 2021-03-31 Xellia Pharmaceuticals Aps Kompozicije glikopeptida
US10067103B2 (en) * 2015-03-02 2018-09-04 Colonaryconcepts Llc Compounds and methods for PEG metabolite and PEG breakdown product assays
US10071141B2 (en) 2015-05-08 2018-09-11 Spectral Platforms, Inc. Albumin-based non-covalent complexes and methods of use thereof
US20200171124A1 (en) 2016-04-15 2020-06-04 Lupin Limited Topical compositions for ophthalmic and otic use
EP3602065A4 (en) 2017-03-20 2020-12-23 Spectral Platforms, Inc. SPECTROSCOPIC METHODS OF DETECTION AND CHARACTERIZATION OF MICROORGANISMS
EP3651739A4 (en) * 2017-07-10 2021-04-07 Contrafect Corporation BLOOD COMPONENT POTENTIALIZATION OF LYTIC PROTEIN ANTIBACTERIAL ACTIVITY AND RELATED METHODS AND USES
CN110183519B (zh) * 2019-05-06 2023-04-11 大邦(湖南)生物制药有限公司 一种达巴万星关键中间体a40926的分离纯化方法
CN112480214B (zh) * 2020-12-14 2023-03-28 成都雅途生物技术有限公司 一种达巴万星关键中间体a40926的制备方法
EP4014965A1 (en) * 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
MX2023008148A (es) 2021-01-11 2023-07-24 Xellia Pharmaceuticals Aps Proceso de sintesis.
WO2024079223A1 (en) * 2022-10-12 2024-04-18 Xellia Pharmaceuticals Aps Liquid dalbavancin composition
WO2024079224A1 (en) * 2022-10-12 2024-04-18 Xellia Pharmaceuticals Aps Liquid dalbavancin composition

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US573679A (en) * 1896-12-22 Apparatus for mowing hay
US541616A (en) * 1895-06-25 Elevator attachment
GB1496386A (en) * 1975-03-05 1977-12-30 Lepetit Spa Antibiotics
US4195079A (en) * 1979-01-31 1980-03-25 Pfizer Inc. New polycyclic ether antibiotic
CA1183789A (en) 1981-08-04 1985-03-12 Kiyoshi Isono Antibiotic 76-11, process for the production thereof, anticoccidiosis agent and domestic animals growth accelerator comprising the same as an effective ingredient
US4578271A (en) 1982-05-24 1986-03-25 Fujisawa Pharmaceutical Co., Ltd. Biologically active WS 6049 substances, a process for the production thereof and their pharmaceutical compositions
FI73697C (fi) * 1982-06-08 1987-11-09 Lepetit Spa Foerfarande foer framstaellning av individuella faktorer 1, 2, 3, 4 och 5 av teikomysin a2.
FR2548021B1 (fr) 1983-06-29 1986-02-28 Dick P R Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels
GB8415092D0 (en) * 1984-06-13 1984-07-18 Lepetit Spa Ester derivatives
GB8425685D0 (en) * 1984-10-11 1984-11-14 Lepetit Spa Antibiotic a 40926 complex
US4914187A (en) * 1984-11-13 1990-04-03 Gruppo Lepetit S.P.A Ester derivatives of antibiotic L 17046
GB8428619D0 (en) * 1984-11-13 1984-12-19 Lepetit Spa Derivatives of antibiotic l 17046
GB8512795D0 (en) 1985-05-21 1985-06-26 Lepetit Spa Increasing ratio of components of teicoplanin a2 complex
GB8531846D0 (en) * 1985-12-30 1986-02-05 Lepetit Spa Antibiotic a 40926 mannosyl aglycon
GB8608809D0 (en) * 1986-04-11 1986-05-14 Lepetit Spa Antibiotic
GB8621912D0 (en) 1986-09-11 1986-10-15 Lepetit Spa Increasing ratio of components of anti-biotic complex
GB8621911D0 (en) * 1986-09-11 1986-10-15 Lepetit Spa Increasing ratio of components of anti-biotic complex
GR871488B (en) 1986-10-10 1987-11-12 Lepetit Spa New antibiotics
GB8715735D0 (en) * 1987-07-03 1987-08-12 Lepetit Spa De-mannosyl teicoplanin derivatives
US4882313A (en) * 1987-07-31 1989-11-21 Smithkline Beckman Corporation Carboxamide derivatives of glycopeptides
GB8726859D0 (en) 1987-11-17 1987-12-23 Lepetit Spa 22-dechlorotei-coplanins
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
FR2628269B1 (fr) * 1988-03-04 1990-07-27 Sgs Thomson Microelectronics Dispositif de demarrage progressif d'une alimentation a decoupage
ES2083374T3 (es) 1988-12-27 1996-04-16 Lepetit Spa Derivados amidicos en posicion c63 de 34-des(acetilglucosaminil)-34-desoxi-teicoplaninas.
IE64155B1 (en) 1989-03-29 1995-07-12 Lepetit Spa New substituted alkylamide derivatives of teicoplanin
JPH03193735A (ja) * 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
US5030619A (en) * 1990-04-16 1991-07-09 Miles Inc. Synergistic fungicidal composition
US5606036A (en) * 1991-03-27 1997-02-25 Gruppo Lepetit Spa Antibiotic A 40926 ester derivatives
JP2783722B2 (ja) * 1991-07-12 1998-08-06 麒麟麦酒株式会社 スピカマイシン誘導体およびそれを含む抗腫瘍剤
KR100242682B1 (ko) 1991-07-29 2000-02-01 클라우디오 쿼르타 항생물질 a 40926의 아미드 유도체
US5750509A (en) * 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
US6384013B1 (en) * 1992-03-19 2002-05-07 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
US5882900A (en) * 1992-09-10 1999-03-16 Gruppo Lepetit S.P.A. Process for the selective increase of production of antibiotic GE 2270 factor a by adding vitamin B12 to nutrient medium
CA2112776C (en) * 1993-01-21 2002-11-12 Masakazu Tsuchiya Process for inhibiting activity of endotoxin
US6455689B1 (en) * 1993-04-30 2002-09-24 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH Antisense-oligonucleotides for transforming growth factor-β (TGF-β)
SI9500039B (sl) * 1995-02-07 2002-02-28 Lek, Nov kombiniran postopek čiščenja Vankomicin hidroklorida
ES2161344T3 (es) * 1995-02-07 2001-12-01 Biosearch Italia Spa Derivados oxazolin-amidicos basicos de los antibioticos ge2270 y similares.
DK0801655T3 (da) * 1995-02-07 1999-02-08 Biosearch Italia Spa Basiske prolinamidderivater af GE 2270 og GE 2270-lignende antibiotika
US5789308A (en) * 1995-06-06 1998-08-04 Advanced Micro Devices, Inc. Manufacturing method for wafer slice starting material to optimize extrinsic gettering during semiconductor fabrication
CA2180206A1 (en) * 1995-06-30 1996-12-31 Motoya Ohshika Freeze-dried preparation for pharmaceutical use
PT836619E (pt) * 1995-07-05 2004-11-30 Aventis Bulk S P A Purificacao de antibioticos dalba-heptidicos por focagem isoelectrica
DE19600590A1 (de) * 1996-01-10 1997-07-24 Tzn Forschung & Entwicklung Schutzvorrichtung für optische Systeme zur Vermeidung von Schäden bei Bestrahlung dieser Systeme mit Laserlicht
ATE231163T1 (de) * 1996-02-14 2003-02-15 Biosearch Italia Spa Derivate des antibiotisch wirkenden faktors ge2270
AU2441697A (en) 1996-04-12 1997-11-07 Eli Lilly And Company Covalently-linked glycopeptide dimers
CA2250578C (en) * 1996-04-23 2003-06-24 Versicor Inc. Improved chemical process for preparing amide derivatives of antibiotic a 40926
US5935238A (en) * 1997-06-19 1999-08-10 Sun Microsystems, Inc. Selection from multiple fetch addresses generated concurrently including predicted and actual target by control-flow instructions in current and previous instruction bundles
JP4204655B2 (ja) * 1997-08-08 2009-01-07 株式会社ルネサステクノロジ パルス出力機能付マイクロコンピュータ
CA2255140A1 (en) 1997-12-23 1999-06-23 Eli Lilly And Company Echinocandin binding domain of 1,3-.beta.-glucan synthase
US6541616B1 (en) * 1998-10-01 2003-04-01 Antex Biologics Inc. Moraxella catarrhalis protein, gene sequence and uses thereof
US6417180B1 (en) 1998-10-07 2002-07-09 University Of Massachusetts Zinc finger-reactive antimicrobial compounds
SI1140993T1 (en) * 1998-12-23 2003-12-31 Theravance, Inc. Glycopeptide derivatives and pharmaceutical compositions containing the same
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
US6770621B2 (en) 2000-05-02 2004-08-03 Theravance, Inc. Polyacid glycopeptide derivatives
WO2003070756A2 (de) 2002-02-18 2003-08-28 Combinature Biopharm Ag Neue glycopeptid-antibiotika und verfahren zu deren synthetisierung
US7119061B2 (en) 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
KR101173310B1 (ko) 2002-11-18 2012-08-10 비큐론 파마세티컬스 인코포레이티드 박테리아 감염 치료를 위한 달바반신 투여 방법

Similar Documents

Publication Publication Date Title
JP2013155188A5 (ja)
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
JP2012193216A5 (ja)
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
NZ714963A (en) Compositions and methods for treating anemia
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
JP2015515985A5 (ja)
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
RU2014141893A (ru) Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких
JP2013541583A5 (ja)
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
DK2802319T3 (da) Fastdosiskombinationsterapi for parkinsons sygdom
JP2017061488A5 (ja)
MX2015016750A (es) Composicion inmunogenica para uso en terapia.
MX2018005298A (es) Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa.
MX2018013475A (es) Acido carboxilico para tratar/prevenir congestion nasal.
MX2018011293A (es) Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma.
JP2013523789A5 (ja)
TN2016000179A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.
JP2010519274A5 (ja)
JP2017515849A5 (ja)
UA69674U (ru) Способ лечения больных на эритематозно-бульозной рожей
JP2015512439A5 (ja)